Aligning Incentives and Leveraging Technology to Improve Clinical Trials for Sponsors and Participants with Meri Beckwith Lindus Health TRANSCRIPT
Release Date: 11/15/2024
Aligning Incentives and Leveraging Technology to Improve Clinical Trials for Sponsors and Participants with Meri Beckwith Lindus Health TRANSCRIPT
Empowered Patient Podcast
Meri Beckwith, Co-Founder of Lindus Health, aims to transform clinical trials by changing the CRO model to leverage technology to improve patient recruitment, retention, and the experience of the sponsors and trial participants. While the compensation model for contract research organizations is often not aligned with trial outcomes, Lindus ties compensation to hitting milestones and outcomes. They emphasize the need for more flexible trial design and a decentralized and hybrid approach to reduce participant burden and bring drugs to market sooner. Meri explains, "This comes back to...
info_outline
Aligning Incentives and Leveraging Technology to Improve Clinical Trials for Sponsors and Participants with Meri Beckwith Lindus Health
Empowered Patient Podcast
Meri Beckwith, Co-Founder of Lindus Health, aims to transform clinical trials by changing the CRO model to leverage technology to improve patient recruitment, retention, and the experience of the sponsors and trial participants. While the compensation model for contract research organizations is often not aligned with trial outcomes, Lindus ties compensation to hitting milestones and outcomes. They emphasize the need for more flexible trial design and a decentralized and hybrid approach to reduce participant burden and bring drugs to market sooner. Meri explains, "This comes back to...
info_outline
AI-Powered Cancer Biomarker Digital Detection Informs and Accelerates Decisions of Pathologists and Oncologists with Greg Hamilton io9 TRANSCRIPT
Empowered Patient Podcast
Greg explains, "For many of these cancers, determining the right cancer treatment is the difference between life and death. When we look at how we treat cancer today, what hasn’t changed is that there’ll be a biopsy. So, they take a piece of the tumor out and send that tumor to a pathologist. Pathologists will take that tumor and put it in a glass slide. They usually use what’s called H&E, they kind of stain it to read it better. But basically, a pathologist is looking under a microscope at the cells, and that’s how we diagnose cancer. That’s the formal way that we diagnose...
info_outline
AI-Powered Cancer Biomarker Digital Detection Informs and Accelerates Decisions of Pathologists and Oncologists with Greg Hamilton io9
Empowered Patient Podcast
Greg Hamilton, CEO of io9, aims to enable precision oncology treatments for patients globally. The company has developed an AI-powered biomarker analysis platform called OncoGaze that can rapidly analyze digital pathology images to identify cancer biomarkers. This enables pathologists to efficiently and quickly digitize and analyze tumor samples and oncologists to start patients on the appropriate targeted therapy much faster. Greg explains, "For many of these cancers, determining the right cancer treatment is the difference between life and death. When we look at how we treat...
info_outline
Leveraging Antibody Phage Display Library to Generate Unique Bispecific Antibodies for Solid Tumors with Dr. Jeng Her AP Biosciences TRANSCRIPT
Empowered Patient Podcast
Dr. Jeng Her, Founder and CEO of AP Biosciences, is developing T-Cube bispecific antibodies that can target cancer cells and engage T-cells to kill them more effectively and safely than existing treatments. The company is focused on treating hard-to-treat cancers such as HER2-positive breast cancer, lung cancer, head and neck cancer, and pancreatic cancer. The T-Cube bispecific antibodies use CD137 instead of CD3 to activate T-cells, which can lead to better efficacy and safety compared to other T-cell engager antibodies. Jeng explains, "So why not just take two, let's say, monospecific...
info_outline
Leveraging Antibody Phage Display Library to Generate Unique Bispecific Antibodies for Solid Tumors with Dr. Jeng Her AP Biosciences
Empowered Patient Podcast
Dr. Jeng Her, Founder and CEO of AP Biosciences, is developing T-Cube bispecific antibodies that can target cancer cells and engage T-cells to kill them more effectively and safely than existing treatments. The company is focused on treating hard-to-treat cancers such as HER2-positive breast cancer, lung cancer, head and neck cancer, and pancreatic cancer. The T-Cube bispecific antibodies use CD137 instead of CD3 to activate T-cells, which can lead to better efficacy and safety compared to other T-cell engager antibodies. Jeng explains, "So why not just take two, let's say, monospecific...
info_outline
Increasing Focus of Medical Device Companies on Regulations and Compliance with Sonia Veluchamy Celegence TRANSCRIPT
Empowered Patient Podcast
Sonia Veluchamy, CEO and Co-founder of Celegence discusses the increasing regulatory requirements and complexities faced by the medical device industry. Celegence works with companies to streamline their regulatory data management processes and adopt advanced technology solutions to manage compliance efficiently. Medical device companies are often slower than pharmaceutical companies to recognize the need to invest in data governance and process optimization to maintain compliance and avoid fines, delays in product approval, and loss of market access. Sonia explains, "The awareness is there,...
info_outline
Increasing Focus of Medical Device Companies on Regulations and Compliance with Sonia Veluchamy Celegence
Empowered Patient Podcast
Sonia Veluchamy, CEO and Co-founder of Celegence discusses the increasing regulatory requirements and complexities faced by the medical device industry. Celegence works with companies to streamline their regulatory data management processes and adopt advanced technology solutions to manage compliance efficiently. Medical device companies are often slower than pharmaceutical companies to recognize the need to invest in data governance and process optimization to maintain compliance and avoid fines, delays in product approval, and loss of market access. Sonia explains, "The awareness is there,...
info_outline
Dissolvable Stent to Treat Peripheral Artery Disease Below the Knee with Dr. Ethan Korngold Abbott TRANSCRIPT
Empowered Patient Podcast
Dr. Ethan Korngold is the chief medical officer and divisional vice president of medical affairs at Abbott’s vascular business, which has developed a dissolvable stent technology to treat peripheral artery disease. PAD disproportionately affects Black and Hispanic communities and is often overlooked because early symptoms can be mistaken for other conditions. The Esprit BTK stent can help open up the smaller arteries below the knee and improve blood flow to the legs and feet to treat PAD and prevent severe complications and amputations. Ethan explains, "So peripheral artery disease...
info_outline
Dissolvable Stent to Treat Peripheral Artery Disease Below the Knee with Dr. Ethan Korngold Abbott
Empowered Patient Podcast
Dr. Ethan Korngold is the chief medical officer and divisional vice president of medical affairs at Abbott’s vascular business, which has developed a dissolvable stent technology to treat peripheral artery disease. PAD disproportionately affects Black and Hispanic communities and is often overlooked because early symptoms can be mistaken for other conditions. The Esprit BTK stent can help open up the smaller arteries below the knee and improve blood flow to the legs and feet to treat PAD and prevent severe complications and amputations. Ethan explains, "So peripheral artery disease...
info_outlineMeri Beckwith, Co-Founder of Lindus Health, aims to transform clinical trials by changing the CRO model to leverage technology to improve patient recruitment, retention, and the experience of the sponsors and trial participants. While the compensation model for contract research organizations is often not aligned with trial outcomes, Lindus ties compensation to hitting milestones and outcomes. They emphasize the need for more flexible trial design and a decentralized and hybrid approach to reduce participant burden and bring drugs to market sooner.
Meri explains, "This comes back to how contract research organizations are paid and compensated where they’re typically paid per hour of input, and it’s not at all tied to the outputs being speed, patient experience, or quality of data. And so we’ve created this monster over the last 10 or 20 years where the cost of clinical trials keeps going up. Patient experience certainly seems to be getting worse. Above all, patients suffer because the direct experience in clinical trials is worse. Still, they have to wait longer and ultimately pay more for new treatments as the cost of those clinical trials is ultimately passed on to patients."
"So essentially, we’re responsible for running the entire clinical trial end to end, but we do that in a very different way and with a very different business model from that of industry incumbents. On the business model front, we provide completely fixed costs for everything and our customers, the companies developing the drugs, only pay us when we hit milestones. In other words, our compensation is tied to the actual trial outcomes, moving the trial along, et cetera. The second difference is under the hood, we have the same level of concierge service - folks who oversee and design the clinical trials, medics and clinicians who are looking after patients. We also have our technology platform to help us find the right patients, get them enrolled in the right trial quickly, and monitor and capture the data as we go – leading to higher quality data."
#LindusHealth #ClinicalResearch #CRO #ClinicalTrialRecruitment #DrugDevelopment
